Sofosbuvir with velpatasvir in treatment-naive noncirrhotic patients with genotype 1 to 6 hepatitis c virus infection

Annals of Internal Medicine

Volumn 163, Issue 11, 2015, Pages 818-826

  Everson, Gregory T ^a   Towner, William J ^b   Davis, Mitchell N ^c   Wyles, David L ^d   Nahass, Ronald G ^e   Thuluvath, Paul J ^f   Etzkorn, Kyle ^g   Hinestrosa, Federico ^h   Tong, Myron ⁱ   Rabinovitz, Mordechai ^j   McNally, John ^k   Brainard, Diana M ^k   Han, Lingling ^k   Doehle, Brian ^k   McHutchison, John G ^k   Morgan, Timothy ^l   Chung, Raymond T ^m   Tran, Tram T ⁿ  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b KAISER PERMANENTE   (United States)

^c Digestive CARE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e ID Care   (United States)

^f MERCY MEDICAL CENTER   (United States)

^g Borland Groover Clinic   (United States)

^h ORLANDO IMMUNOLOGY CENTER   (United States)

ⁱ HUNTINGTON MEDICAL RESEARCH INSTITUTES   (United States)

^j UNIVERSITY OF PITTSBURGH   (United States)

^k McHutchison Gilead Sciences   (United States)

^l VA LONG BEACH HEALTHCARE SYSTEM   (United States)

^m MASSACHUSETTS GENERAL HOSPITAL   (United States)

ⁿ CEDARS SINAI MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; HEMOGLOBIN; RIBAVIRIN; SOFOSBUVIR; VELPATASVIR; ANTIVIRUS AGENT; CARBAMIC ACID DERIVATIVE; FUSED HETEROCYCLIC RINGS;

ADULT; ARTICLE; BILIRUBIN BLOOD LEVEL; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EVENING DOSAGE; FATIGUE; FEMALE; FOLLOW UP; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 3; HEPATITIS C VIRUS GENOTYPE 4; HEPATITIS C VIRUS GENOTYPE 5; HEPATITIS C VIRUS GENOTYPE 6; HUMAN; INSOMNIA; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTICENTER STUDY; NAUSEA; NEUTROPHIL COUNT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS RESISTANCE; AGED; ANTIVIRAL RESISTANCE; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DRUG ADMINISTRATION; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; ANTIVIRAL AGENTS; CARBAMATES; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; HUMANS; MALE; MIDDLE AGED; SOFOSBUVIR; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84948705255     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/M15-1000     Document Type: Article

References (19)

1. World Health Organization. Hepatitis C. Fact sheet no. 164. Geneva: World Health Organization; 2015. Accessed at www.who.int/mediacentre/factsheets/fs164/en on 31 July 2015.
2. Westbrook RH, Dusheiko G. Natural history of hepatitis C. J Hepatol. 2014;61:S58-68. [PMID: 25443346]
3. Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol. 2013;10:553-62. [PMID: 23817321]
4. Nyalakonda H, Utay NS. A new era of therapy for hepatitis C virus infection. Curr Opin Infect Dis. 2015;28:471-8. [PMID: 26203851]
5. Narayanan S, Townsend K, Macharia T, Majid A, Nelson A, Redfield RR, et al. Favorable adverse event profile of sofosbuvir/ribavirin compared to boceprevir/interferon/ribavirin for treatment of hepatitis C. Hepatol Int. 2014;8:560-6. [PMID: 26202761]
6. Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014;61:S45-57. [PMID: 25086286]
7. Goossens N, Negro F. Is genotype 3 of the hepatitis C virus the new villain? Hepatology. 2014;59:2403-12. [PMID: 24155107]
8. Buti M, Esteban R. Hepatitis C virus genotype 3: a genotype that is not easy-To-Treat. Expert Rev Gastroenterol Hepatol. 2015;9:375-85. [PMID: 25222289]
9. American Association for the Study of Liver Diseases, Infectious Diseases Society of America. HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. 2015. Accessed at www.hcvguidelines.org on 28 July 2015.
10. European Association for Study of Liver. EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol. 2015;63:199-236. [PMID: 25911336]
11. Gilead Sciences. Sovaldi (sofosbuvir) United States prescribing information. Foster City, CA: Gilead Sciences; 2013. Accessed at www.gilead.com/~/media/Files/pdfs/medicines/liver-disease/sovaldi/sovaldi-pi.pdf on 7 August 2015.
12. Cheng G, Yu M, Peng B, Lee YJ, Trejo-Martin A, Gong R, et al. GS-5816, a novel second generation HCV NS5A inhibitor with preclinical pan-genotypic antiviral activity and a high resistance barrier. J Hepatol. 2013;58:S484.
13. Lawitz E, Freilich B, Link J, German P, Mo H, Han L, et al. A phase 1, randomized, dose-ranging study of GS-5816, a once-daily NS5A inhibitor, in patients with genotype 1-4 hepatitis C virus. J Viral Hepat. 2015. [PMID: 26183611]
14. Mogalian E, German P, Brainard D, Link J, McNally J, Han L, et al. Lack of a clinically significant pharmacokinetic drug-drug interaction between sofosbuvir and GS-5816 in healthy volunteers. Presented at The Liver Meeting 2013: 64th Annual Meeting of the American Association for the Study of Liver Diseases, Washington, DC, 1-5 November 2013.
15. German P, Mathias AA, Pang PS, Yang C, Han L, Link JO, et al. Healthy volunteer first-in-human evaluation of GS-5816, a novel second generation broad-genotypic NS5A inhibitor with potential for once-daily dosing. Presented at the European Association for the Study of the Liver 48th Annual Meeting, Amsterdam, the Netherlands, 24-28 April 2013.
16. Merck. Rebetol (ribavirin) capsules: US prescribing information. Whitehouse Station, NJ: Merck; 2003 (revised 2015). Accessed atwww.merck.com/product/usa/pi-circulars/r/rebetol/rebetol-pi.pdf on 31 July 2015.
17. Clopper CJ, Pearson ES. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika. 1934;26:404-13.
18. Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, et al; ION-1 Investigators. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370:1889-98. [PMID: 24725239]
19. Zeuzem S, Dusheiko GM, Salupere R, Mangia A, Flisiak R, Hyland RH, et al; VALENCE Investigators. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med. 2014;370:1993-2001. [PMID: 24795201] doi:10.1056/NEJMoa1316145